BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18006112)

  • 1. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
    Kalmadi SR; Rankin C; Kraut MJ; Jacobs AD; Petrylak DP; Adelstein DJ; Keohan ML; Taub RN; Borden EC
    Lung Cancer; 2008 May; 60(2):259-63. PubMed ID: 18006112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
    Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
    Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
    van Haarst JM; Baas P; Manegold Ch; Schouwink JH; Burgers JA; de Bruin HG; Mooi WJ; van Klaveren RJ; de Jonge MJ; van Meerbeeck JP
    Br J Cancer; 2002 Feb; 86(3):342-5. PubMed ID: 11875695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
    Nowak AK; Byrne MJ; Williamson R; Ryan G; Segal A; Fielding D; Mitchell P; Musk AW; Robinson BW
    Br J Cancer; 2002 Aug; 87(5):491-6. PubMed ID: 12189542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
    Castagneto B; Zai S; Dongiovanni D; Muzio A; Bretti S; Numico G; Botta M; Sinaccio G
    Am J Clin Oncol; 2005 Jun; 28(3):223-6. PubMed ID: 15923792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
    Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
    J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
    Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
    J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
    Favaretto AG; Aversa SM; Paccagnella A; Manzini Vde P; Palmisano V; Oniga F; Stefani M; Rea F; Bortolotti L; Loreggian L; Monfardini S
    Cancer; 2003 Jun; 97(11):2791-7. PubMed ID: 12767092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
    J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
    Pinto C; Marino A; De Pangher Manzini V; Benedetti G; Galetta D; Mazzanti P; Del Conte G; dell'Amore D; Piana E; Giaquinta S; Lopez M; Martoni A
    Lung Cancer; 2006 May; 52(2):199-206. PubMed ID: 16542747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
    Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST; Park JY; Lee J; Park JO; Park YS; Lim HY; Kang WK; Park SH
    Jpn J Clin Oncol; 2010 Nov; 40(11):1031-6. PubMed ID: 20534685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.